Jiukuan Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jiukuan Hao has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Jianxiong Jiang
Department of Pharmaceutical Sciences and Drug Discovery Center, College of Pharmacy, University of Tennessee Health Science Center, Memphis, USA
6 shared publicationsXiaotian Xu
Department of Neurology, The Affiliated Hospital of Yangzhou University, Jiangsu Province, Xiaotian Xu, China
5 shared publicationsChangwen Zhang
Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
3 shared publicationsLangni Liu
Center for Neuroimmunology and Glial Biology, Institute of Molecular Medicine, University of Texas Health Science Center, Houston, USA
2 shared publicationsMei Xin
Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital medical Center, Cincinnati, USA
2 shared publicationsAdnan Akif
Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, USA
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Wiley in British Journal of Pharmacology
Highly potent, brain‐penetrant EP 2 receptor antagonists for the treatment of permanent focal cerebral ischaemia in male and female mice
Background and Purpose: Cerebral ischaemia is a leading cause of death in older adults and imposes a substantial global economic burden. Recent studies indicate that inhibiting the Gα s ‐coupled EP 2 receptor reduces ischaemic brain injury by modulating neuroinflammation. However, these findings derive from the transient middle cerebral artery occlusion (tMCAO) model, which represents only a small subset of large‐vessel occlusion (LVO) cases with successful recanalisation. Experimental Approach: We characterised the pharmacokinetic parameters of selective EP 2 antagonists CJ‐18, CJ‐19 and CJ‐21 that we recently developed. We evaluated their therapeutic efficacy in mice subjected to permanent MCAO (pMCAO), a model that more accurately reflects the majority of LVO cases, and assessed the impact of EP 2 inhibition on brain injury and inflammation. Finally, we examined the effects of EP 2 inhibition in neuron–glia mixed cultures exposed to oxygen–glucose deprivation (OGD) without reoxygenation. Key Results: After systemic administration in mice, new compounds exhibited favourable plasma half‐lives and brain penetration. In the pMCAO model, treatment with EP 2 antagonists significantly reduced brain infarction in both male and female mice, in a dose‐dependent manner, whilst improving sensorimotor performance without affecting muscle strength. These benefits were accompanied by reduced neuronal death, lowered pro‐inflammatory cytokines and attenuated reactive gliosis within the ischaemic penumbra. In addition, EP 2 inhibition by CJ‐18 conferred marked neuroprotection in neuron–glia co‐cultures exposed to prolonged OGD, preserving neurite integrity and postsynaptic density. Conclusions and Implications: This proof‐of‐concept study supports our drug‐like EP 2 receptor antagonists, particularly CJ‐18, as potential treatments for permanent focal cerebral ischaemia.
- 13 October 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessHighly potent, brain‐penetrant EP 2 receptor antagonists for the treatment of permanent focal cerebral ischaemia in male and female mice
Background and Purpose: Cerebral ischaemia is a leading cause of death in older adults and imposes a substantial global economic burden. Recent studies indicate that inhibiting the Gα s ‐coupled EP 2 receptor reduces ischaemic brain injury by modulating neuroinflammation. However, these findings derive from the transient middle cerebral artery occlusion (tMCAO) model, which represents only a small subset of large‐vessel occlusion (LVO) cases with successful recanalisation. Experimental Approach: We characterised the pharmacokinetic parameters of selective EP 2 antagonists CJ‐18, CJ‐19 and CJ‐21 that we recently developed. We evaluated their therapeutic efficacy in mice subjected to permanent MCAO (pMCAO), a model that more accurately reflects the majority of LVO cases, and assessed the impact of EP 2 inhibition on brain injury and inflammation. Finally, we examined the effects of EP 2 inhibition in neuron–glia mixed cultures exposed to oxygen–glucose deprivation (OGD) without reoxygenation. Key Results: After systemic administration in mice, new compounds exhibited favourable plasma half‐lives and brain penetration. In the pMCAO model, treatment with EP 2 antagonists significantly reduced brain infarction in both male and female mice, in a dose‐dependent manner, whilst improving sensorimotor performance without affecting muscle strength. These benefits were accompanied by reduced neuronal death, lowered pro‐inflammatory cytokines and attenuated reactive gliosis within the ischaemic penumbra. In addition, EP 2 inhibition by CJ‐18 conferred marked neuroprotection in neuron–glia co‐cultures exposed to prolonged OGD, preserving neurite integrity and postsynaptic density. Conclusions and Implications: This proof‐of‐concept study supports our drug‐like EP 2 receptor antagonists, particularly CJ‐18, as potential treatments for permanent focal cerebral ischaemia.
- Open Access
- 3 June 2025
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 22 (1) , 1-16
Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia
Background: As a key inflammatory factor, the nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome plays a crucial role in neuroinflammation and the progression of neurodegenerative diseases. Dysregulation of NLRP3 signaling can trigger various inflammatory responses in the brain, contributing to the development of neurodegenerative diseases such as ischemic stroke, vascular dementia (VaD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Therefore, the NLRP3 signaling pathway is a promising therapeutic target for the treatment of neurodegenerative diseases, including VaD. Methods: In this study, we investigated the therapeutic effects of a synthetic sulfonylurea NLRP3 inhibitor, AMS-17, in a VaD mouse model using bilateral common carotid artery stenosis (BCAS) and elucidated the underlying mechanisms. All mice were randomly divided into three groups: Sham, VaD + Vehicle, and VaD + AMS-17. Cognitive function was assessed using the Y-maze and Morris water maze (MWM) on the 50th day after BCAS. Brain sections and blood serum samples were collected for biomarker analysis and immunohistochemistry. Neurodegeneration, expressions of the molecules involved in the NLRP3 signaling pathways, tight junction proteins, and myelination were assessed using western blotting and immunofluorescence (IF). The levels of Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-4 (IL-4) in the blood were measured using ELISA. Results: AMS-17 treatment improved cognitive function, enhanced blood-brain barrier (BBB) integrity, and promoted remyelination in VaD mice. Additionally, AMS-17 reduced neurodegeneration and decreased the expression of NLRP3 and its associated proteins, Apoptosis-associated speck-like protein (ASC), and cleaved caspase-1 in the brain. It also lowered pro-inflammatory TNF-α and IL-1β levels, while increasing the anti-inflammatory IL-4 level in the blood. Conclusions: The findings of this study provide the first promising evidence for the use of AMS-17 in VaD treatment in mice. This study introduces AMS-17 as a novel chemical scaffold with NLRP3 inhibitory activity, which can be further developed for the treatment of VaD in humans. Clinical trial number: Not applicable. Graphical
- 3 June 2025
- Published by Springer Nature in Fluids and Barriers of the CNS
- Vol. 22 (1) , 1-16
Open AccessTargeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia
Background: As a key inflammatory factor, the nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome plays a crucial role in neuroinflammation and the progression of neurodegenerative diseases. Dysregulation of NLRP3 signaling can trigger various inflammatory responses in the brain, contributing to the development of neurodegenerative diseases such as ischemic stroke, vascular dementia (VaD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). Therefore, the NLRP3 signaling pathway is a promising therapeutic target for the treatment of neurodegenerative diseases, including VaD. Methods: In this study, we investigated the therapeutic effects of a synthetic sulfonylurea NLRP3 inhibitor, AMS-17, in a VaD mouse model using bilateral common carotid artery stenosis (BCAS) and elucidated the underlying mechanisms. All mice were randomly divided into three groups: Sham, VaD + Vehicle, and VaD + AMS-17. Cognitive function was assessed using the Y-maze and Morris water maze (MWM) on the 50th day after BCAS. Brain sections and blood serum samples were collected for biomarker analysis and immunohistochemistry. Neurodegeneration, expressions of the molecules involved in the NLRP3 signaling pathways, tight junction proteins, and myelination were assessed using western blotting and immunofluorescence (IF). The levels of Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-4 (IL-4) in the blood were measured using ELISA. Results: AMS-17 treatment improved cognitive function, enhanced blood-brain barrier (BBB) integrity, and promoted remyelination in VaD mice. Additionally, AMS-17 reduced neurodegeneration and decreased the expression of NLRP3 and its associated proteins, Apoptosis-associated speck-like protein (ASC), and cleaved caspase-1 in the brain. It also lowered pro-inflammatory TNF-α and IL-1β levels, while increasing the anti-inflammatory IL-4 level in the blood. Conclusions: The findings of this study provide the first promising evidence for the use of AMS-17 in VaD treatment in mice. This study introduces AMS-17 as a novel chemical scaffold with NLRP3 inhibitory activity, which can be further developed for the treatment of VaD in humans. Clinical trial number: Not applicable. Graphical
- 18 May 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (7) , 4593-4611
Effect of TDP43-CTFs35 on Brain Endothelial Cell Functions in Cerebral Ischemic Injury
Pathological changes in the brain endothelium play an important role in the progression of ischemic stroke and the compromised BBB under ischemic stroke conditions cause neuronal damage. However, the pathophysiological mechanisms of the BBB under normal conditions and under ischemic stroke conditions have not been fully elucidated. The present study demonstrated that knockdown of TAR DNA-binding protein 43 (TDP-43) or overexpression of TDP43-CTFs35 inhibited tight junction protein expression, and mammalian sterile-20-like 1/2 (MST1/2) and YES-associated protein (YAP) phosphorylation in brain ECs and suppressed brain EC migration in vitro. The cytoplasmic TDP43-CTFs35 level was increased in brain ECs 24 h and 72 h after MCAO, but it disappeared 1 week after cerebral ischemia. The expression of tight junction proteins was also significantly deceased 24 h after MCAO and then gradually recovered at 72 h and 1 week after MCAO. The level of YAP phosphorylation was first significantly decreased 24 h after MCAO and then increased 72 h and 1 week after MCAO, accompanied by nuclear YAP translocation. The underlying mechanism is TDP43-CTFs35-mediated inhibition of Hippo signaling pathway activity through the dephosphorylation of MST1/2, which leads to the inhibition of YAP phosphorylation and the subsequent impairment of brain EC migration and tight junction protein expression. This study provides new insights into the mechanisms of brain vascular EC regulation, which may impact on BBB integrity after cerebral ischemic injury.
- 18 May 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (7) , 4593-4611
Effect of TDP43-CTFs35 on Brain Endothelial Cell Functions in Cerebral Ischemic Injury
Pathological changes in the brain endothelium play an important role in the progression of ischemic stroke and the compromised BBB under ischemic stroke conditions cause neuronal damage. However, the pathophysiological mechanisms of the BBB under normal conditions and under ischemic stroke conditions have not been fully elucidated. The present study demonstrated that knockdown of TAR DNA-binding protein 43 (TDP-43) or overexpression of TDP43-CTFs35 inhibited tight junction protein expression, and mammalian sterile-20-like 1/2 (MST1/2) and YES-associated protein (YAP) phosphorylation in brain ECs and suppressed brain EC migration in vitro. The cytoplasmic TDP43-CTFs35 level was increased in brain ECs 24 h and 72 h after MCAO, but it disappeared 1 week after cerebral ischemia. The expression of tight junction proteins was also significantly deceased 24 h after MCAO and then gradually recovered at 72 h and 1 week after MCAO. The level of YAP phosphorylation was first significantly decreased 24 h after MCAO and then increased 72 h and 1 week after MCAO, accompanied by nuclear YAP translocation. The underlying mechanism is TDP43-CTFs35-mediated inhibition of Hippo signaling pathway activity through the dephosphorylation of MST1/2, which leads to the inhibition of YAP phosphorylation and the subsequent impairment of brain EC migration and tight junction protein expression. This study provides new insights into the mechanisms of brain vascular EC regulation, which may impact on BBB integrity after cerebral ischemic injury.
- 31 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 58, 116645
Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation
- 31 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 58, 116645
Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation
- 20 December 2021
- Published by Elsevier in Brain Research Bulletin
- Vol. 179, 74-82
4R-cembranoid protects neuronal cells from oxygen–glucose deprivation by modulating microglial cell activation
- 20 December 2021
- Published by Elsevier in Brain Research Bulletin
- Vol. 179, 74-82
4R-cembranoid protects neuronal cells from oxygen–glucose deprivation by modulating microglial cell activation
- Open Access
- 20 August 2021
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 13
Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice
Growing evidence suggests that hypertension and aging are prominent risk factors for the development of late-onset Alzheimer’s disease (LOAD) by inducement of neuroinflammation. Recent study showed that neuroinflammation via activated microglia induces reactive astrocytes, termed A1 astrocytes, that highly upregulate numerous classical complement cascade genes that are destructive to neurons in neurodegeneration diseases. Moreover, triggering receptor expressed on myeloid cells 2 (TREM2) is considered as one of the strongest single-allele genetic risk factors and plays important roles in neuroinflammation for LOAD. However, the mechanisms of microglia in the regulation of A1 astrocytic activation are still not clear. We introduced angiotensin II-induced hypertension in middle-aged mice and found that hypertension-upregulated TREM2 expression and A1 astrocytic activation were involved in neuroinflammation in the animal models used in this study. The in vitro results revealed that overexpression of microglial TREM2 not only mitigated microglial inflammatory response but also had salutary effects on reverse A1 astrocytic activation and neuronal toxicity.
- 20 August 2021
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 13
Open AccessMicroglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice
Growing evidence suggests that hypertension and aging are prominent risk factors for the development of late-onset Alzheimer’s disease (LOAD) by inducement of neuroinflammation. Recent study showed that neuroinflammation via activated microglia induces reactive astrocytes, termed A1 astrocytes, that highly upregulate numerous classical complement cascade genes that are destructive to neurons in neurodegeneration diseases. Moreover, triggering receptor expressed on myeloid cells 2 (TREM2) is considered as one of the strongest single-allele genetic risk factors and plays important roles in neuroinflammation for LOAD. However, the mechanisms of microglia in the regulation of A1 astrocytic activation are still not clear. We introduced angiotensin II-induced hypertension in middle-aged mice and found that hypertension-upregulated TREM2 expression and A1 astrocytic activation were involved in neuroinflammation in the animal models used in this study. The in vitro results revealed that overexpression of microglial TREM2 not only mitigated microglial inflammatory response but also had salutary effects on reverse A1 astrocytic activation and neuronal toxicity.
- Open Access
- 3 August 2021
- Published by Springer Nature in Research Square
The TDP43 CFTS Affect Brain Endothelial Cell Functions by Regulating YAP and Tight Junction Proteins in Cerebral Ischemic Injury.
Background: As important components of the blood-brain barrier (BBB), brain endothelial cells (ECs) interact with pericytes, astrocytes, neurons, microglia and extracellular matrix in the neurovascular unit to maintain central nerve system (CNS) homeostasis and regulate neurological functions. Pathological changes in brain endothelium plays an important role in progression of ischemic stroke. The compromised BBB under ischemic stroke condition causes neuronal damage. However, the pathophysiological mechanisms of BBB in normal and under ischemic stroke condition has not been fully elucidated.Methods: C57bl/6 mice were subjected to 1-hour transient middle cerebral occlusion (tMCAO) model, and collected the brain samples after reperfusion for 24hours, 72hours and 1week. Lentivirus (YAP/TAZ shRNA), adenovirus (YAPS112A), TDP43 siRNA, TDP43-CTFS35 overexpression plasmid, Oxygen-glucose deprivation (OGD), and lipopolysaccharides (LPS) were applied to brain endothelial cells in vitro experiments. Brain endothelial cells (ECs) functions were tested by cell proliferation, migration and cell viability. Hippo signaling pathway was examined by immunofluorescence and western blotting.Results: The present study demonstrates that TDP43 is an essential gene to regulate brain ECs normal function, and knockdown of TDP43 reduces tight junction protein expression and inhibits brain ECs migration. Furthermore, ischemic injury and inflammation induce cytoplasmic TDP43-CTFS35 aggregation brain ECs, which weaken TDP43 full-length’s function leading to impairing tight junction (TJ) protein expression and cell migration. The expression of cytoplasmic TDP43-CTFS35 in brain ECs increased at 24 hours and 72 hours after MCAO, but disappeared at 1 week after MCAO. The expressions of TJ proteins, ZO-1 and claudin-5, and expression of P-YAP are associated with the dynamic changes of TDP43-CTFS35 expression in brain ECs after MCAO. The underlying mechanism of TDP43-CTFS35’s effects on brain ECs is that TDP43-CTFS35 turns off the Hippo signaling pathway by inhibition of PMST1/2 phosphorylation leading to de-phosphorylate YAP, and subsequently causes brain ECs functional changes.Conclusions: The present study provides new insight knowledge regarding the mechanisms of brain vascular ECs regulation and pathological change in the BBB after cerebral ischemic injury.
- 3 August 2021
- Published by Springer Nature in Research Square
Open AccessThe TDP43 CFTS Affect Brain Endothelial Cell Functions by Regulating YAP and Tight Junction Proteins in Cerebral Ischemic Injury.
Background: As important components of the blood-brain barrier (BBB), brain endothelial cells (ECs) interact with pericytes, astrocytes, neurons, microglia and extracellular matrix in the neurovascular unit to maintain central nerve system (CNS) homeostasis and regulate neurological functions. Pathological changes in brain endothelium plays an important role in progression of ischemic stroke. The compromised BBB under ischemic stroke condition causes neuronal damage. However, the pathophysiological mechanisms of BBB in normal and under ischemic stroke condition has not been fully elucidated.Methods: C57bl/6 mice were subjected to 1-hour transient middle cerebral occlusion (tMCAO) model, and collected the brain samples after reperfusion for 24hours, 72hours and 1week. Lentivirus (YAP/TAZ shRNA), adenovirus (YAPS112A), TDP43 siRNA, TDP43-CTFS35 overexpression plasmid, Oxygen-glucose deprivation (OGD), and lipopolysaccharides (LPS) were applied to brain endothelial cells in vitro experiments. Brain endothelial cells (ECs) functions were tested by cell proliferation, migration and cell viability. Hippo signaling pathway was examined by immunofluorescence and western blotting.Results: The present study demonstrates that TDP43 is an essential gene to regulate brain ECs normal function, and knockdown of TDP43 reduces tight junction protein expression and inhibits brain ECs migration. Furthermore, ischemic injury and inflammation induce cytoplasmic TDP43-CTFS35 aggregation brain ECs, which weaken TDP43 full-length’s function leading to impairing tight junction (TJ) protein expression and cell migration. The expression of cytoplasmic TDP43-CTFS35 in brain ECs increased at 24 hours and 72 hours after MCAO, but disappeared at 1 week after MCAO. The expressions of TJ proteins, ZO-1 and claudin-5, and expression of P-YAP are associated with the dynamic changes of TDP43-CTFS35 expression in brain ECs after MCAO. The underlying mechanism of TDP43-CTFS35’s effects on brain ECs is that TDP43-CTFS35 turns off the Hippo signaling pathway by inhibition of PMST1/2 phosphorylation leading to de-phosphorylate YAP, and subsequently causes brain ECs functional changes.Conclusions: The present study provides new insight knowledge regarding the mechanisms of brain vascular ECs regulation and pathological change in the BBB after cerebral ischemic injury.